04:50 PM EDT, 03/17/2025 (MT Newswires) -- Gyre Therapeutics ( GYRE ) reported Q4 breakeven late Monday, compared with a net loss of $1.39 per diluted share a year earlier.

One analyst polled by FactSet expected earnings of $0.04 per share.

Revenue for the quarter ended Dec. 31 was $27.9 million, up from $27.1 million a year earlier.

One analyst surveyed by FactSet expected $23.5 million.

The company said it expects 2025 revenue between $118 million and $128 million.

One analyst polled by FactSet expects $135.7 million.